• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

OncoZenge

6.32 SEK

-0.32 %

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.32 %
+5.33 %
-0.47 %
-6.51 %
-2.32 %
+14.70 %
-4.53 %
-45.98 %
-48.35 %

OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Read more
Market cap
88.78M SEK
Turnover
276.96K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
3.9.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release6/5/2026, 1:10 PM

OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement

OncoZenge
Press release6/3/2026, 7:30 AM

OncoZenge AB Appoints Linda Nord as Head of Regulatory Affairs

OncoZenge
Press release6/2/2026, 7:50 AM

OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici

OncoZenge

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/27/2026, 1:15 PM

BULLETIN FROM THE ANNUAL GENERAL MEETING OF ONCOZENGE

OncoZenge
Press release5/26/2026, 10:19 AM

Redeye: OncoZenge (Q1 Review): Final CTA approval received, initiating pivotal study

OncoZenge
Regulatory press release5/26/2026, 9:20 AM

OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge™

OncoZenge
Regulatory press release5/26/2026, 6:00 AM

OncoZenge AB Interim Report January 1 - March 31, 2026

OncoZenge
Regulatory press release5/22/2026, 5:00 AM

OncoZenge enters into a loan agreement of SEK 2 million with Linc AB

OncoZenge
Press release5/19/2026, 11:40 AM

OncoZenge Provides Regulatory Update on BupiZenge™ Phase III Trial

OncoZenge
Regulatory press release4/30/2026, 6:00 AM

OncoZenge AB Publishes Annual Report for 2025

OncoZenge
Press release4/28/2026, 12:50 PM

OncoZenge Receives Conditional Acceptance for the Clinical Phase III Trial (‘BEAM-Pain’) of BupiZenge™ from European Authorities

OncoZenge
Regulatory press release4/24/2026, 6:00 AM

Notice of the Annual General Meeting of OncoZenge AB (publ)

OncoZenge
Press release4/2/2026, 10:55 AM

OncoZenge Confirms Submission of Responses to EMA on the BupiZenge™ Phase III Trial (BZ003)

OncoZenge
Press release4/1/2026, 7:15 AM

OncoZenge Reports Positive Stability Results for BupiZenge™ as Key Enabler for the Upcoming Phase III Trial

OncoZenge
Press release2/26/2026, 2:29 PM

Redeye: OncoZenge (Q4 review): Final preparations ahead of phase III

OncoZenge
Regulatory press release2/26/2026, 7:00 AM

OncoZenge AB Year-end Report January 1 – December 31, 2025

OncoZenge
Press release2/12/2026, 9:22 AM

OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical

OncoZenge
Press release2/4/2026, 8:40 AM

OncoZenge AB Unveils Key Insights from UCLA Patient Engagement Study on Oral Mucositis Pain Management

OncoZenge
Press release2/2/2026, 8:30 AM

OncoZenge AB Appoints Dr. Marie-Louise Fjällskog as Chief Medical Officer

OncoZenge
Press release1/30/2026, 2:40 PM

OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge™ Technology Batch, Advancing Toward Clinical Trials

OncoZenge